Cortigent, Inc. is engaged in developing targeted neurostimulation systems that help patients to recover critical body functions. Its technology combines advanced neuroscience with microelectronics, software, and data processing capabilities to provide artificial vision and potentially restore muscle movement. Its commercial system, Argus II, provides artificial vision to various profoundly blind people who were implanted with this device. It is further engaged in exploring the application of its Orion neurostimulation technology for accelerating the recovery of arm and hand function in patients who are partially paralyzed due to stroke. The Company is also engaged in developing a platform technology with multiple potential applications, which includes its miniature neurostimulation device with 60 independent-cortical stimulation channels, supported by data from the Argus II and Orion programs, which serves as a platform for targeting other conditions with high unmet medical need.